Agios Pharmaceuticals (AGIO) Analysts See $-1.74 EPS; Egerton Capital Uk Llp Has Cut Microsoft (MSFT) Position

October 14, 2017 - By Darrin Black

Egerton Capital Uk Llp decreased Microsoft Corp (MSFT) stake by 0.74% reported in 2017Q2 SEC filing. Egerton Capital Uk Llp sold 29,726 shares as Microsoft Corp (MSFT)’s stock rose 4.75%. The Egerton Capital Uk Llp holds 3.97 million shares with $273.53 million value, down from 4.00M last quarter. Microsoft Corp now has $596.85 billion valuation. The stock increased 0.48% or $0.37 on October 13, reaching $77.49. About 15.34M shares traded. Microsoft Corporation (NASDAQ:MSFT) has risen 34.52% since October 14, 2016 and is uptrending. It has outperformed by 17.82% the S&P500.

Analysts expect Agios Pharmaceuticals Inc (NASDAQ:AGIO) to report $-1.74 EPS on November, 2.They anticipate $0.11 EPS change or 6.75% from last quarter’s $-1.63 EPS. After having $-1.78 EPS previously, Agios Pharmaceuticals Inc’s analysts see -2.25% EPS growth. The stock decreased 1.35% or $0.98 on October 13, reaching $71.35. About 245,472 shares traded. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 8.52% since October 14, 2016 and is uptrending. It has underperformed by 8.18% the S&P500.

Since May 1, 2017, it had 0 insider buys, and 4 insider sales for $497,855 activity. The insider Schenkein David P sold $150,180. $95,885 worth of Agios Pharmaceuticals Inc (NASDAQ:AGIO) was sold by Cantley Lewis Clayton Jr..

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals had 38 analyst reports since July 23, 2015 according to SRatingsIntel. As per Friday, August 7, the company rating was maintained by Canaccord Genuity. The stock has “Buy” rating by SunTrust on Wednesday, March 30. The stock has “Outperform” rating by Northland Capital on Thursday, July 23. The stock has “Buy” rating by Oppenheimer on Thursday, June 1. Needham initiated the stock with “Buy” rating in Monday, October 24 report. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) has “Buy” rating given on Tuesday, June 6 by Cowen & Co. The firm earned “Buy” rating on Monday, June 26 by Oppenheimer. On Wednesday, March 2 the stock rating was initiated by Janney Capital with “Neutral”. The firm earned “Neutral” rating on Friday, August 19 by BTIG Research. Canaccord Genuity upgraded the stock to “Buy” rating in Monday, June 13 report.

Investors sentiment increased to 2.04 in 2017 Q2. Its up 0.71, from 1.33 in 2017Q1. It is positive, as 14 investors sold Agios Pharmaceuticals Inc shares while 32 reduced holdings. 22 funds opened positions while 72 raised stakes. 44.72 million shares or 14.71% more from 38.98 million shares in 2017Q1 were reported. Amalgamated Bank holds 0.01% or 6,930 shares in its portfolio. Canada Pension Plan Investment Board invested in 0.01% or 48,100 shares. Nationwide Fund Advsr invested in 0% or 4,604 shares. Maryland-based Brown Advisory Incorporated has invested 0.04% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Fmr Ltd Liability Corporation reported 7.23M shares. Clear Harbor Asset Limited Liability Corp owns 4,325 shares. Proshare Advisors Ltd Limited Liability Company stated it has 25,623 shares. Pictet Asset Mgmt holds 0% or 18,300 shares in its portfolio. Jennison Assocs Limited Liability Corporation reported 166,455 shares. The Illinois-based Balyasny Asset Management Ltd Llc has invested 0.2% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Asset Mngmt One holds 0.01% or 48,111 shares. 154,100 are held by Cap Sarl. California-based Tarbox Family Office Inc has invested 0% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Columbus Circle Investors holds 17,640 shares or 0.01% of its portfolio. Invesco Limited reported 0.02% stake.

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $3.45 billion. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. It currently has negative earnings. The Company’s cancer product candidates are enasidenib and ivosidenib , which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Since May 1, 2017, it had 0 insider buys, and 8 selling transactions for $1.04 billion activity. 4,927 Microsoft Corporation (NASDAQ:MSFT) shares with value of $338,709 were sold by Capossela Christopher C. On Wednesday, May 3 Morfit G Mason sold $481.95M worth of Microsoft Corporation (NASDAQ:MSFT) or 7.00M shares. 2.50M shares were sold by GATES WILLIAM H III, worth $173.51 million on Tuesday, May 2. COURTOIS JEAN PHILIPPE also sold $1.84 million worth of Microsoft Corporation (NASDAQ:MSFT) shares.

Investors sentiment decreased to 0.82 in Q2 2017. Its down 0.02, from 0.84 in 2017Q1. It is negative, as 39 investors sold MSFT shares while 982 reduced holdings. 132 funds opened positions while 703 raised stakes. 5.53 billion shares or 0.72% more from 5.49 billion shares in 2017Q1 were reported. Somerset Tru Communication has invested 3.12% in Microsoft Corporation (NASDAQ:MSFT). Fic, New York-based fund reported 69,319 shares. Argent Company reported 128,540 shares. Mercer Capital Advisers Inc holds 4.36% of its portfolio in Microsoft Corporation (NASDAQ:MSFT) for 84,387 shares. Mogy Joel R Invest Counsel, California-based fund reported 343,530 shares. Morgens Waterfall Vintiadis & reported 50,000 shares. Ibm Retirement Fund stated it has 2.63% in Microsoft Corporation (NASDAQ:MSFT). Mycio Wealth Prtnrs Ltd Co holds 0.4% or 49,539 shares. 64,038 were accumulated by Independent Investors. Cubist Systematic Strategies Ltd Liability invested in 45,140 shares. Lehman Resource Inc holds 3,160 shares or 0.12% of its portfolio. Loudon Investment Mgmt Ltd Com has invested 3.32% in Microsoft Corporation (NASDAQ:MSFT). Axa accumulated 3.45M shares. Glg Lc holds 1.55% or 367,177 shares. Fenimore Asset owns 0.01% invested in Microsoft Corporation (NASDAQ:MSFT) for 3,056 shares.